Protagenic Therapeutics, Inc.
PTIX
$0.218
-$0.0001-0.05%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 739.80K | 287.90K | 453.30K | 277.60K | 200.80K |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 1.64M | 652.10K | 1.67M | 1.74M | 1.21M |
Operating Income | -1.64M | -652.10K | -1.67M | -1.74M | -1.21M |
Income Before Tax | -1.55M | -640.80K | -1.61M | -1.72M | -1.68M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -1.55M | -640.80K | -1.61M | -1.72M | -1.68M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -1.55M | -640.80K | -1.61M | -1.72M | -1.68M |
EBIT | -1.64M | -652.10K | -1.67M | -1.74M | -1.21M |
EBITDA | -1.63M | -639.50K | -1.65M | -1.73M | -1.19M |
EPS Basic | -0.25 | -0.14 | -0.36 | -0.39 | -0.38 |
Normalized Basic EPS | -0.17 | -0.09 | -0.23 | -0.24 | -0.17 |
EPS Diluted | -0.25 | -0.14 | -0.36 | -0.39 | -0.38 |
Normalized Diluted EPS | -0.17 | -0.09 | -0.23 | -0.24 | -0.17 |
Average Basic Shares Outstanding | 6.19M | 4.53M | 4.44M | 4.44M | 4.39M |
Average Diluted Shares Outstanding | 6.19M | 4.53M | 4.44M | 4.44M | 4.39M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |